Statins for progression of aortic valve stenosis and the best evidence for making decisions in health care

dc.contributor.authorThiago, Luciana
dc.contributor.authorTsuji, Selma Rumiko [UNIFESP]
dc.contributor.authorAtallah, Alvaro Nagib [UNIFESP]
dc.contributor.authorPuga, Maria Eduarda dos Santos [UNIFESP]
dc.contributor.authorGois, Aecio Flavio Teixeira de [UNIFESP]
dc.contributor.institutionFac Med Marilia Famema
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionBrazilian Cochrane Ctr
dc.date.accessioned2018-06-18T11:54:46Z
dc.date.available2018-06-18T11:54:46Z
dc.date.issued2011-01-06
dc.description.abstractIn the Western world, calcified aortic valve stenosis is the most common form of valvular heart disease, affecting up to 3% of adults over the age of 75 years. It is a gradually progressive disease, characterized by a long asymptomatic phase that may last for several decades, followed by a short symptomatic phase associated with severe restriction of the valve orifice. Investigations on treatments for aortic valve stenosis are still in progress. Thus, it is believed that calcification of aortic valve stenosis is similar to the process of atherosclerosis that occurs in coronary artery disease. Recent studies have suggested that cholesterol lowering through the use of station may have a salutary effect on the progression of aortic valve stenosis.en
dc.description.affiliationFac Med Marilia Famema, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo Escola Paulista Med Unifesp EP, Hosp Sao Paulo, Dept Emergency Serv, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo Escola Paulista Med Unifesp EP, Hosp Sao Paulo, Emergency Intens Care Unit, Sao Paulo, Brazil
dc.description.affiliationBrazilian Cochrane Ctr, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo Escola Paulista Med Unifesp EP, Hosp Sao Paulo, Dept Emergency Serv, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo Escola Paulista Med Unifesp EP, Hosp Sao Paulo, Emergency Intens Care Unit, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent41-45
dc.identifierhttp://dx.doi.org/10.1590/S1516-31802011000100008
dc.identifier.citationSao Paulo Medical Journal. Sao Paulo: Associacao Paulista Medicina, v. 129, n. 1, p. 41-45, 2011.
dc.identifier.doi10.1590/S1516-31802011000100008
dc.identifier.fileS1516-31802011000100008.pdf
dc.identifier.issn1516-3180
dc.identifier.scieloS1516-31802011000100008
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/45552
dc.identifier.wosWOS:000288620300008
dc.language.isoeng
dc.publisherAssociacao Paulista Medicina
dc.relation.ispartofSao Paulo Medical Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAortic valve stenosisen
dc.subjectHydroxymethylglutaryl-CoA reductase inhibitorsen
dc.subjectAtherosclerosisen
dc.subjectDisease progressionen
dc.subjectReview [publication type]en
dc.titleStatins for progression of aortic valve stenosis and the best evidence for making decisions in health careen
dc.title.alternativeEstatinas para a progressão da estenose da valva aórtica e a melhor evidência para tomar decisões em saúdept
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
S1516-31802011000100008.pdf
Tamanho:
109.18 KB
Formato:
Adobe Portable Document Format
Descrição:
Coleções